University of Washington
This phase II trial tests the effect of intravesical nadofaragene firadenovec in combination with enfortumab vedotin and pembrolizumab before (neoadjuvant) radical cystectomy in treating patients with muscle invasive bladder cancer. The combination of enfortumab vedotin and pembrolizumab are already considered standard of care in the treatment of muscle invasive bladder cancer. This trial attempts to determine whether the addition of nadofaragene firadenovec to the current standard regiment is safe and can improve oncological outcomes for those with muscle invasive bladder cancer. Nadofaragene firadenovec, a type of intravesical gene therapy, is a weakened adenovirus that carries a copy of the gene for interferon alfa-2b. This medication gets absorbed by the bladder and stimulates the bladder to naturally create interferon alfa-2b, which is thought to kill bladder cancer. Nadofaragene firadenovec is given in a solution that is placed directly into the bladder (intravesical) using a thin tube called a catheter. It is a medication that is already Food and Drug Administration approved for the treatment of non-muscle invasive bladder cancer. Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Investigators aim to assess whether adding intravesical nadofaragene firadenovec to the current recommended treatment of enfortumab vedotin and pembrolizumab before undergoing a radical cystectomy may be safe, tolerable, and/or effective in treating patients with muscle-invasive bladder cancer.
OUTLINE: Patients receive standard of care neoadjuvant therapies for muscle invasive bladder cancer including: enfortumab vedotin intravenously (IV) on days 1 and 8 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 3-4 cycles in the absence of disease progression or unacceptable toxicity. In addition, patients will also receive nadofaragene firadenovec intravesically on day 1 of cycle 1 (one total dose during the entire neoadjuvant period). Starting 4-8 weeks after completion of treatment, patients undergo radical cystectomy (RC) per standard clinical care. Ad…
Inclusion Criteria: * Age ≥ 18 years at the time of screening * Ability to understand and willingness to sign the written informed consent document * Patients with confirmed muscle-invasive urothelial carcinoma of the bladder (cT2-4a, N0-1, M0 or cT1, N1, M0), who are planning to undergo RC * Pure urothelial or mixed histologic subtypes are allowed if urothelial is the primary histology (regardless of the % of conventional urothelial histology; however, any % of small cell/neuroendocrine is excluded) * Eligible to receive neoadjuvant enfortumab vedotin and pembrolizumab (EV-P) per the patient…
Given intravesically
Given IV
Given IV
Undergo RC
Undergo urine and blood sample collection
Undergo CT or PET/CT
Undergo PET/CT
Undergo MRI